C4 Therapeutics, Inc. (CCCC) Return on equity 2021–2025
C4 Therapeutics, Inc. (CCCC) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
-40.9%FY2025 · since FY2021: -21.5% → -40.9%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -40.9% | +7.8 pp |
| FY2024 | -48.8% | +5.1 pp |
| FY2023 | -53.8% | -9.5 pp |
| FY2022 | -44.3% | -22.8 pp |
| FY2021 | -21.5% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice